S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in

Syneos Health Stock Forecast, Price & News

+0.88 (+1.14 %)
(As of 01/20/2021 12:00 AM ET)
Today's Range
Now: $78.01
50-Day Range
MA: $69.08
52-Week Range
Now: $78.01
Volume667,271 shs
Average Volume690,376 shs
Market Capitalization$8.11 billion
P/E Ratio42.86
Dividend YieldN/A
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications solutions, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic agreement with Daiichi Sankyo, Inc. for the development of Daiichi Sankyo'S Adc oncology pipeline; and a partnership with VBI Vaccines Inc. for the commercialization of VBI's 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Syneos Health logo


Overall MarketRank

1.55 out of 5 stars

Medical Sector

368th out of 1,928 stocks

Commercial Physical Research Industry

8th out of 42 stocks

Analyst Opinion: 1.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:SYNH



Sales & Book Value

Annual Sales$4.68 billion
Cash Flow$5.41 per share
Book Value$29.19 per share


Net Income$131.26 million


Market Cap$8.11 billion
Next Earnings Date2/18/2021 (Estimated)
+0.88 (+1.14 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

How has Syneos Health's stock been impacted by COVID-19?

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SYNH shares have increased by 36.1% and is now trading at $78.01.
View which stocks have been most impacted by COVID-19

Is Syneos Health a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Syneos Health stock.
View analyst ratings for Syneos Health
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Syneos Health?

Wall Street analysts have given Syneos Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Syneos Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Syneos Health's CEO?

1,428 employees have rated Syneos Health CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Syneos Health's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Syneos Health

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) announced its quarterly earnings results on Thursday, October, 29th. The company reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.79 by $0.25. The firm earned $1.10 billion during the quarter, compared to the consensus estimate of $1.12 billion. Syneos Health had a net margin of 4.28% and a return on equity of 10.02%. The company's revenue for the quarter was down 6.6% compared to the same quarter last year. During the same period last year, the business earned $0.87 earnings per share.
View Syneos Health's earnings history

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, January, 13th. The company provided earnings per share guidance of 3.33-3.46 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.40. The company issued revenue guidance of $4.37-4.44 billion, compared to the consensus revenue estimate of $4.42 billion.

What price target have analysts set for SYNH?

12 brokerages have issued 1-year price targets for Syneos Health's shares. Their forecasts range from $52.00 to $85.00. On average, they expect Syneos Health's stock price to reach $72.14 in the next twelve months. This suggests that the stock has a possible downside of 7.5%.
View analysts' price targets for Syneos Health
or view Wall Street analyst' top-rated stocks.

Who are some of Syneos Health's key competitors?

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Square (SQ), Advanced Micro Devices (AMD), The Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

Who are Syneos Health's key executives?

Syneos Health's management team includes the following people:
  • Mr. Alistair Macdonald, CEO & Director (Age 50, Pay $1.76M)
  • Mr. Jason M. Meggs, Chief Financial Officer (Age 44, Pay $760.92k)
  • Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 44, Pay $823.57k)
  • Ms. Michelle Keefe, Pres of Commercial Solutions (Age 53, Pay $798.49k)
  • Mr. Paul D. Colvin, Pres of Clinical Solutions (Age 50, Pay $794.52k)
  • Mr. Robert Parks, Exec. VP & Chief Accounting Officer
  • Dr. Judith Ng-Cashin, Chief Scientific Officer
  • Mr. Larry A. Pickett Jr., Chief Information & Digital Officer
  • Ronnie Speight, Sr. VP of Investor Relations
  • Ms. Kristen Spensieri, Global Head of Corp. Communications & Marketing

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.46%), AMI Asset Management Corp (0.11%), Dalton Greiner Hartman Maher & Co. (0.11%), Buffington Mohr McNeal (0.07%), Louisiana State Employees Retirement System (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Syneos Health stock include Alistair Macdonald, International Corp/Ma Advent, Jason M Meggs, John M Dineen, Michelle Keefe, Paul Colvin, Robert Parks and Thomas H Lee Advisors, Llc.
View institutional ownership trends for Syneos Health

Which institutional investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, Peregrine Capital Management LLC, and Pacer Advisors Inc.. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald, International Corp/Ma Advent, Jason M Meggs, Michelle Keefe, Robert Parks, and Thomas H Lee Advisors, Llc.
View insider buying and selling activity for Syneos Health
or view top insider-selling stocks.

Which institutional investors are buying Syneos Health stock?

SYNH stock was bought by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Crossmark Global Holdings Inc., Buffington Mohr McNeal, Louisiana State Employees Retirement System, Park Avenue Securities LLC, First Hawaiian Bank, and State of Alaska Department of Revenue. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, John M Dineen, and Paul Colvin.
View insider buying and selling activity for Syneos Health
or or view top insider-buying stocks.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $78.01.

How big of a company is Syneos Health?

Syneos Health has a market capitalization of $8.11 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.

What is Syneos Health's official website?

The official website for Syneos Health is www.syneoshealth.com.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.